Abstract

This study aims to assess the clinical efficacy of combining chemotherapy with vascular targeted agents in managing advanced liver cancer. A total of 86 patients diagnosed with advanced liver cancer between March 2020 and August 2022 were enrolled in this study. They were randomly divided into an observation group (n=43) receiving chemotherapy combined with vascular targeted agents and a control group (n=43) receiving chemotherapy alone. The study compared treatment outcomes, tumor marker levels, inflammatory cytokine profiles, quality of life, and adverse reactions between the two groups. Prior to treatment, no significant differences were observed in the levels of alpha-fetoprotein, vascular endothelial growth factor, fibroblast growth factor, and carcinoembryonic antigen between the observation and control groups (p>0.05). Post-treatment, the observation group exhibited significantly lower alpha-fetoprotein, vascular endothelial growth factor, fibroblast growth factor, and carcinoembryonic antigen levels compared to the control group (p<0.05). Pre-treatment, there were no noteworthy differences in interleukin-6, interleukin-10, and tumor necrosis factor-alpha levels between the two groups (p>0.05). Post-treatment, interleukin-6 and tumor necrosis factor-alpha levels decreased in the observation group, while interleukin-10 levels increased in comparison to the control group (p<0.05). Before treatment, there were no significant disparities in quality of life scores between the groups (p>0.05). However, post-treatment, the observation group showed higher quality of life scores than the control group (p<0.05). The incidence of adverse reactions did not significantly differ between the observation and control groups (p>0.05). Combining chemotherapy with vascular targeted agents for treating advanced liver cancer is associated with notable reductions in tumor marker levels, modulation of immune function, and enhanced patient quality of life. This combined approach is both safe and reliable, warranting its consideration for wider clinical application and promotion.